Menu

Notable Science Quotes

Brexit's effect on science, melding disciplines, and more

Aug 1, 2016
The Scientist Staff

© ISTOCK.COM/ANDREW LINSCOTT

Being in the E.U. gives us access to ideas, people and to investment in science. That, combined with mobility [of EU scientists], gives us increased collaboration, increased transfer of people, ideas, and science—all of which history has shown us drives science.

—Nobel laureate Paul Nurse, director of the Francis Crick Institute and immediate past president of the Royal Society, speaking four months before UK citizens voted to leave the European Union in the historic “Brexit” referendum (BBC News, February 26)

 

For science to thrive it must have access to the single market, and we do need free movement. We could negotiate that outside the E.U., which will probably end up costing more money and we would have little influence [in deciding research priorities]. Or perhaps we should just reconsider this entire mess and see if there is something that can be done to reconsider this once the dust has settled.

Paul Nurse, on how the June 23 "Brexit" vote to leave the European Union could impact scientific research in the U.K. (BBC News, June 29)

 

Convergence has grown from a little seedling to a sprouting plant, but to become a great tree and orchard yielding fruit for decades into the future, it needs to be nourished, expanded, and cultivated now. Students need to be educated, collaborations need to be encouraged, and resources need to be committed to make sure convergence thrives.

—Nobel laureate Phillip Sharp, on the need to merge historically disparate disciplines, such as physics, computer science, mathematics, and the life sciences in order to achieve long-standing goals in biomedicine (MIT News, June 23)

 

By bringing together doctors and data like never before, precision medicine aims to deliver the right treatments in the right dosage at the right time—every time. It helps target the causes of a condition rather than just the symptoms. This is one of the greatest opportunities we’ve ever seen for new medical breakthroughs, but it only works if we collect enough information first.

—President Barack Obama, in a Boston Globe opinion piece about his administration’s efforts to make personalized medicine a broader reality (July 7)

 

Earth needs a virtual country: #Rationalia, with a one-line Constitution: All policy shall be based on the weight of evidence.

—Astrophysicist Neil deGrasse Tyson, in a recent tweet (June 29)

 

Tyson is a very smart man, but this is a very stupid tweet, and a very stupid idea. It is even, we might say, unreasonable and without sufficient evidence. Of course imagining a society in which all actors behave logically sounds appealing. But employing logic to consider the concept reveals that there could be no such thing.

Jeffrey Guhin, a University of California, Los Angeles, sociologist, criticizing Neil deGrasse Tyson’s controversial #Rationalia tweet (Slate, July 5)

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.